These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 36932776)

  • 1. A clinic-epidemiological study of 148 patients of pemphigus at Lady Reading Hospital, Peshawar: a case series.
    Paracha MM; Sagheer F; Khan AQ
    J Pak Med Assoc; 2023 Mar; 73(3):659-662. PubMed ID: 36932776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pemphigus disease activity measurements: pemphigus disease area index, autoimmune bullous skin disorder intensity score, and pemphigus vulgaris activity score.
    Rahbar Z; Daneshpazhooh M; Mirshams-Shahshahani M; Esmaili N; Heidari K; Aghazadeh N; Hejazi P; Ghajarzadeh M; Chams-Davatchi C
    JAMA Dermatol; 2014 Mar; 150(3):266-72. PubMed ID: 24429657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris.
    Olszewska M; Kolacinska-Strasz Z; Sulej J; Labecka H; Cwikla J; Natorska U; Blaszczyk M
    Am J Clin Dermatol; 2007; 8(2):85-92. PubMed ID: 17428113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of rituximab and conventional adjuvant therapy for pemphigus vulgaris: A retrospective analysis.
    Agarwal A; Hall RP; Bañez LL; Cardones AR
    PLoS One; 2018; 13(9):e0198074. PubMed ID: 30252855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Patterns, Survival, Comorbidities, and Treatment Regimens in 149 Patients With Pemphigus in Tuscany (Italy): A 12-Year Hospital-Based Study.
    Quintarelli L; Coi A; Maglie R; Corrà A; Mariotti EB; Aimo C; Ruffo di Calabria V; Verdelli A; Bianchi B; Del Bianco E; Antiga E; Caproni M
    Front Immunol; 2022; 13():895490. PubMed ID: 35880183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical, immunological profile and follow up of patients with pemphigus: A study from India.
    Ramassamy S; Agrawal P; Sathishkumar D; Mathew L; Peter JV; Mani T; George R
    Indian J Dermatol Venereol Leprol; 2018; 84(4):408-413. PubMed ID: 29536971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors Associated With Complete Remission After Rituximab Therapy for Pemphigus.
    Kushner CJ; Wang S; Tovanabutra N; Tsai DE; Werth VP; Payne AS
    JAMA Dermatol; 2019 Dec; 155(12):1404-1409. PubMed ID: 31642878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab/IVIG in pemphigus - a 10-year study with a long follow-up.
    Hamadah I; Chisti MA; Haider M; Binamer Y; Alajlan S; Aleyouni Y; Alfadley A
    J Dermatolog Treat; 2019 Mar; 30(2):170-175. PubMed ID: 29889591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pediatric autoimmune blistering disorders - a five-year demographic profile and therapy experience.
    Mahajan R; Handa S; Kumar S; Chatterji D; Saikia UN; De D
    Int J Dermatol; 2022 Dec; 61(12):1511-1518. PubMed ID: 35894223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early rituximab treatment is associated with increased and sustained remission in pemphigus patients: A retrospective cohort of 99 patients.
    Nosrati A; Mimouni T; Hodak E; Gdalevich M; Oren-Shabtai M; Levi A; Mimouni D; Leshem YA
    Dermatol Ther; 2022 May; 35(5):e15397. PubMed ID: 35194896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab Therapy for Treatment of Pemphigus in Southeast Asians.
    Kanokrungsee S; Anuntrangsee T; Tankunakorn J; Srisuwanwattana P; Suchonwanit P; Chanprapaph K
    Drug Des Devel Ther; 2021; 15():1677-1690. PubMed ID: 33911853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab in childhood and juvenile autoimmune bullous diseases as first-line and second-line treatment: a case series of 13 patients.
    Kianfar N; Dasdar S; Mahmoudi H; Tavakolpour S; Balighi K; Daneshpazhooh M
    J Dermatolog Treat; 2022 Mar; 33(2):869-874. PubMed ID: 32589481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of rituximab therapy in patients with pemphigus vulgaris: first report from Turkey.
    Uzun S; Bilgiç Temel A; Akman Karakaş A; Ergün E; Özkesici B; Eskiocak AH; Erat A; Uğurlu N; Nazlım B; Koç S; Bozkurt S; Dicle Ö; Alpsoy E; Yılmaz E
    Int J Dermatol; 2016 Dec; 55(12):1362-1368. PubMed ID: 27653507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durable remission of pemphigus with a fixed-dose rituximab protocol.
    Heelan K; Al-Mohammedi F; Smith MJ; Knowles S; Lansang P; Walsh S; Shear NH
    JAMA Dermatol; 2014 Jul; 150(7):703-8. PubMed ID: 24500264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of the Effects of Rituximab Monotherapy on Different Subsets of Circulating T-Regulatory Cells and Clinical Disease Severity in Severe Pemphigus Vulgaris.
    Bhattacharjee R; De D; Handa S; Minz RW; Saikia B; Joshi N
    Dermatology; 2016; 232(5):572-577. PubMed ID: 27576321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pemphigus vulgaris: a clinical study of 44 cases over a 20-year period.
    Svecova D
    Int J Dermatol; 2015 Oct; 54(10):1138-44. PubMed ID: 26394602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab therapy in pediatric pemphigus patients: A retrospective analysis of five Turkish patients and review of the literature.
    Bilgic-Temel A; Özgen Z; Harman M; Kapıcıoğlu Y; Uzun S
    Pediatr Dermatol; 2019 Sep; 36(5):646-650. PubMed ID: 31355479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety analysis of rituximab in 146 Indian pemphigus patients: A retrospective single-center review of up to 68 months follow-up.
    De D; Bishnoi A; Handa S; Mahapatra T; Mahajan R
    Indian J Dermatol Venereol Leprol; 2020; 86(1):39-44. PubMed ID: 31089006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintenance therapy with azathioprine prolonged duration of remission for pemphigus patients who received rituximab as first-line or add-on therapy.
    Cho YT; Huang YM; Wang LF; Chu CY
    J Formos Med Assoc; 2020 Jan; 119(1 Pt 2):230-237. PubMed ID: 31103376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective analysis of a single-center clinical experience toward development of curative treatment of 123 pemphigus patients with a long-term follow-up: efficacy and safety of the multidrug protocol combining intravenous immunoglobulin with the cytotoxic immunosuppressor and mitochondrion-protecting drugs.
    Grando SA
    Int J Dermatol; 2019 Jan; 58(1):114-125. PubMed ID: 30047585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.